Abu Dhabi Gears Up for Season 2 of the Autonomous Racing League: Returns with New Teams, Upgraded Autonomous Super Formula Model, and US$ 2.25 Million Prize Pot
ASPIRE, the innovation acceleration arm of Abu Dhabi’s Advanced Technology Research Council (ATRC), has officially launched the second season of the Abu Dhabi Autonomous Racing League (A2RL), with a confirmed race day set for 26 April 2025, at Yas Marina Circuit. A2RL returns attracting an even broader global footprint with the addition of four new international teams and the reveal of an upgraded Dallara built Super Formula Emirates Autonomous Vehicle (EAV24) designed to push the boundaries of AI in motorsport. Competitors will race for a share of the impressive US$ 2.25 million prize pool.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241014594129/en/
A2RL Season 2 Race Day confirmed for 26 April 2025, at Abu Dhabi’s iconic Yas Marina Circuit (Photo: AETOSWire)
Following a successful inaugural race in April 2024, which featured teams from the USA, Germany, Switzerland, Hungary, Italy, Singapore, China, and the UAE, A2RL is expanding its global roster with the addition of four new teams: AiPEX Racing from the US,Aladin Innovation from France, SEVRUS Japan (TGM Grand Prix) from Japan, and a team from the UAE’s Technology Innovation Institute (TII). These new entrants will join the original teams from Season 1 in undergoing a rigorous simulation phase in November, where they will face track conditions to finalize the complete team roster. The race format for the upcoming season will be revealed following the simulation challenge.
In the simulation phase, teams will prove their ability to control their race cars under challenging conditions such as GPS failures, sensor malfunctions, and meet quality gateways to demonstrate overtaking skills. Teams must also showcase strategies for tire and brake warming, perform hot laps, and even race against virtual opponents. Only those who meet these high standards will qualify for the final competition.
The race promises to showcase some of the world's brightest engineers and programmers, with these teams harnessing the power of artificial intelligence (AI) to code autonomous race cars. The league is evolving into a global AI sport, where the combination of innovation and high-speed competition takes center stage.
H.E. Faisal Al Bannai, Adviser to the UAE President and Secretary General of the Advanced Technology Research Council, underscored the global impact of A2RL, stating: “A2RL is more than just a race; it’s a critical platform for showcasing the power of AI-driven solutions and their potential to transform entire industries. By pushing the boundaries of what’s possible with autonomous technology, we are accelerating innovation across sectors and positioning the UAE as a leader in the global AI landscape.”
Stephane Timpano, CEO of ASPIRE, added, “The second season of A2RL is set to be even more exhilarating, with new teams pushing the limits of AI integration in motorsport. Our upgraded race car, designed with next-gen autonomous tech, will challenge teams to take their coding and engineering to new heights. This league is more than just a competition—it’s a glimpse into the future of AI-driven sports.”
At GITEX Global, Dubai's premier technology event, attendees were given a first look at the upgraded EAV24, A2RL’s next-generation autonomous race car. This model, the body panels of which are crafted from sustainable bio-composite materials, features a sleek design inspired by digital algorithms and AI-driven data patterns, underscoring the event’s core focus on AI innovation. The EAV24 will be at the center of the competition, where teams will battle to develop AI systems that can outsmart and outperform their rivals on the track.
The league's first season saw a remarkable turnout, with over 10,000 spectators witnessing the event live at Yas Marina Circuit, and more than 1 million global viewers streaming the race online. The second season aims to build on this success, cementing A2RL’s position as a pioneering force in both motorsport and the advancement of AI.
A2RL’s mission extends beyond racing—it is about accelerating the development of autonomous systems across a variety of platforms and building public trust in the safety and reliability of this emerging technology. In addition to car racing, the league encompasses other cutting-edge competitions, such as autonomous drone racing and autonomous buggies, allowing for the testing and refinement of technologies in diverse environments. The competition offers OEMs (Original Equipment Manufacturers) and automakers a risk-free environment to explore and develop autonomous innovations, driving advancements that will one day impact the broader mobility sector.
For an exclusive preview of the EAV24 and further insights into the future of AI-driven racing, visit ATRC’s stand at Hall 17-B10 at GITEX Global.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20241014594129/en/
Contacts
Dalia Awdi
+971501945368
Dalia.Awdi@edelman.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 22:46:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 22:35:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 21:32:00 EET | Press release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 14:00:00 EET | Press release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 14:00:00 EET | Press release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom